{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019741","form_type":"8-K","ticker":null,"cik":"0001476963","company_name":"Scorpius Holdings, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.188851+00:00","generated_at":"2026-06-07T14:07:08.524646+00:00","sec_items":["1.01","2.03","3.02","3.03","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NightHawk Biosciences divests Elusys to CEO-controlled buyer; $500k upfront, $2.25M note, royalty","bullets":["Buyer paid $500k cash and assumed ~$40M in liabilities; receives Elusys equity and 'NightHawk' name.","Convertible note: $2.25M at 1% interest, matures in 1 year; conversion price set at 110% of 7-day VWAP.","NightHawk to receive 3% royalty on ANTHIM (anthrax antitoxin) sales through June 2031, with $5M minimum by 2028.","Post-transaction, NightHawk expects to eliminate $40M in contractual obligations and reduce annual expenses by $13M.","CEO Jeffrey Wolf and CFO William Ostrander retain roles at NightHawk and also serve as officers of Buyer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019741","json":"https://secwatch.observer/filing/0001558370-23-019741.json","markdown":"https://secwatch.observer/filing/0001558370-23-019741.md","text":"https://secwatch.observer/filing/0001558370-23-019741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/0001558370-23-019741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/nhwk-20231211x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:07:08.524646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ab09a74cb816095882d451b383e6dec667a346c","claim":"Scorpius Holdings, Inc. incurred convertible notes of aggregate amount of $2,250,000 with Elusys Holdings Inc. at 1% per annum maturing one-year anniversary of its issuance.","evidence_excerpt":"convertible promissory note in the aggregate amount of $2,250,000 (the “Note”), the conversion of which is subject to obtaining stockholder approval of the issuance of shares of the Company’s common stock upon such conversion. The Note will bear interest at a rate of 1% per annum, mature on the one-year anniversary of its issuance","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/0001558370-23-019741-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"aggregate amount of $2,250,000"},{"label":"Counterparty","value":"Elusys Holdings Inc."},{"label":"Rate","value":"1% per annum"},{"label":"Maturity","value":"one-year anniversary of its issuance"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"37b59f0e032ffef470ab4a72f48b6bd5668ed6a2","claim":"Scorpius Holdings, Inc. entered into Asset and Equity Interests Purchase Agreement with Elusys Holdings Inc. valued at $500,000 (effective 2023-12-11).","evidence_excerpt":"On December 11, 2023, NightHawk Biosciences, Inc. (the “Company”) entered into an Asset and Equity Interests Purchase Agreement (the “Agreement”) with Elusys Holdings Inc., a Delaware corporation (“Buyer”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/0001558370-23-019741-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Elusys Holdings Inc."},{"label":"Value","value":"$500,000"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}